![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LSM5 |
Gene summary for LSM5 |
![]() |
Gene information | Species | Human | Gene symbol | LSM5 | Gene ID | 23658 |
Gene name | LSM5 homolog, U6 small nuclear RNA and mRNA degradation associated | |
Gene Alias | YER146W | |
Cytomap | 7p14.3 | |
Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | Q9Y4Y9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23658 | LSM5 | GSM4909282 | Human | Breast | IDC | 1.62e-45 | 8.29e-01 | -0.0288 |
23658 | LSM5 | GSM4909285 | Human | Breast | IDC | 6.58e-06 | 3.10e-01 | 0.21 |
23658 | LSM5 | GSM4909286 | Human | Breast | IDC | 1.46e-03 | 1.28e-01 | 0.1081 |
23658 | LSM5 | GSM4909290 | Human | Breast | IDC | 1.58e-19 | 6.43e-01 | 0.2096 |
23658 | LSM5 | GSM4909293 | Human | Breast | IDC | 4.88e-03 | 2.73e-01 | 0.1581 |
23658 | LSM5 | GSM4909294 | Human | Breast | IDC | 1.51e-13 | 3.92e-01 | 0.2022 |
23658 | LSM5 | GSM4909296 | Human | Breast | IDC | 5.60e-14 | 2.95e-01 | 0.1524 |
23658 | LSM5 | GSM4909297 | Human | Breast | IDC | 3.30e-12 | 2.83e-02 | 0.1517 |
23658 | LSM5 | GSM4909298 | Human | Breast | IDC | 2.77e-02 | 2.80e-01 | 0.1551 |
23658 | LSM5 | GSM4909301 | Human | Breast | IDC | 1.58e-09 | 4.30e-01 | 0.1577 |
23658 | LSM5 | GSM4909304 | Human | Breast | IDC | 2.14e-03 | 2.82e-01 | 0.1636 |
23658 | LSM5 | GSM4909306 | Human | Breast | IDC | 1.07e-05 | 4.35e-01 | 0.1564 |
23658 | LSM5 | GSM4909308 | Human | Breast | IDC | 6.27e-13 | 4.89e-01 | 0.158 |
23658 | LSM5 | GSM4909311 | Human | Breast | IDC | 8.95e-34 | -3.51e-01 | 0.1534 |
23658 | LSM5 | GSM4909312 | Human | Breast | IDC | 5.40e-08 | -7.90e-02 | 0.1552 |
23658 | LSM5 | GSM4909315 | Human | Breast | IDC | 5.28e-15 | 5.77e-01 | 0.21 |
23658 | LSM5 | GSM4909316 | Human | Breast | IDC | 2.74e-13 | 6.27e-01 | 0.21 |
23658 | LSM5 | GSM4909319 | Human | Breast | IDC | 1.25e-38 | -2.56e-01 | 0.1563 |
23658 | LSM5 | GSM4909320 | Human | Breast | IDC | 6.56e-05 | -6.20e-02 | 0.1575 |
23658 | LSM5 | GSM4909321 | Human | Breast | IDC | 1.42e-11 | -2.84e-02 | 0.1559 |
Page: 1 2 3 4 5 6 7 8 9 10 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00083809 | Breast | Precancer | RNA splicing | 65/1080 | 434/18723 | 1.27e-12 | 2.53e-10 | 65 |
GO:00003759 | Breast | Precancer | RNA splicing, via transesterification reactions | 52/1080 | 324/18723 | 1.74e-11 | 2.22e-09 | 52 |
GO:00003779 | Breast | Precancer | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 51/1080 | 320/18723 | 3.55e-11 | 4.04e-09 | 51 |
GO:00003989 | Breast | Precancer | mRNA splicing, via spliceosome | 51/1080 | 320/18723 | 3.55e-11 | 4.04e-09 | 51 |
GO:00064028 | Breast | Precancer | mRNA catabolic process | 31/1080 | 232/18723 | 1.12e-05 | 2.93e-04 | 31 |
GO:00064018 | Breast | Precancer | RNA catabolic process | 34/1080 | 278/18723 | 2.88e-05 | 6.39e-04 | 34 |
GO:00346558 | Breast | Precancer | nucleobase-containing compound catabolic process | 42/1080 | 407/18723 | 1.91e-04 | 3.06e-03 | 42 |
GO:00467007 | Breast | Precancer | heterocycle catabolic process | 44/1080 | 445/18723 | 3.49e-04 | 4.88e-03 | 44 |
GO:00442708 | Breast | Precancer | cellular nitrogen compound catabolic process | 44/1080 | 451/18723 | 4.64e-04 | 6.12e-03 | 44 |
GO:00194397 | Breast | Precancer | aromatic compound catabolic process | 44/1080 | 467/18723 | 9.55e-04 | 1.07e-02 | 44 |
GO:19013617 | Breast | Precancer | organic cyclic compound catabolic process | 45/1080 | 495/18723 | 1.73e-03 | 1.74e-02 | 45 |
GO:000838014 | Breast | IDC | RNA splicing | 73/1434 | 434/18723 | 1.27e-10 | 1.57e-08 | 73 |
GO:000037514 | Breast | IDC | RNA splicing, via transesterification reactions | 58/1434 | 324/18723 | 9.44e-10 | 9.58e-08 | 58 |
GO:000037714 | Breast | IDC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 57/1434 | 320/18723 | 1.60e-09 | 1.49e-07 | 57 |
GO:000039814 | Breast | IDC | mRNA splicing, via spliceosome | 57/1434 | 320/18723 | 1.60e-09 | 1.49e-07 | 57 |
GO:000640113 | Breast | IDC | RNA catabolic process | 38/1434 | 278/18723 | 3.54e-04 | 5.16e-03 | 38 |
GO:000640213 | Breast | IDC | mRNA catabolic process | 33/1434 | 232/18723 | 4.12e-04 | 5.66e-03 | 33 |
GO:190136112 | Breast | IDC | organic cyclic compound catabolic process | 56/1434 | 495/18723 | 2.12e-03 | 1.99e-02 | 56 |
GO:004670012 | Breast | IDC | heterocycle catabolic process | 51/1434 | 445/18723 | 2.51e-03 | 2.25e-02 | 51 |
GO:003465513 | Breast | IDC | nucleobase-containing compound catabolic process | 47/1434 | 407/18723 | 3.12e-03 | 2.63e-02 | 47 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0301814 | Oral cavity | OSCC | RNA degradation | 59/3704 | 79/8465 | 2.05e-08 | 1.91e-07 | 9.70e-08 | 59 |
hsa0304017 | Oral cavity | OSCC | Spliceosome | 123/3704 | 217/8465 | 7.21e-05 | 2.74e-04 | 1.40e-04 | 123 |
hsa0304026 | Oral cavity | LP | Spliceosome | 106/2418 | 217/8465 | 1.30e-10 | 2.40e-09 | 1.55e-09 | 106 |
hsa0301823 | Oral cavity | LP | RNA degradation | 39/2418 | 79/8465 | 6.98e-05 | 4.38e-04 | 2.83e-04 | 39 |
hsa0304036 | Oral cavity | LP | Spliceosome | 106/2418 | 217/8465 | 1.30e-10 | 2.40e-09 | 1.55e-09 | 106 |
hsa0301833 | Oral cavity | LP | RNA degradation | 39/2418 | 79/8465 | 6.98e-05 | 4.38e-04 | 2.83e-04 | 39 |
hsa030188 | Prostate | BPH | RNA degradation | 29/1718 | 79/8465 | 5.17e-04 | 2.67e-03 | 1.65e-03 | 29 |
hsa0304010 | Prostate | BPH | Spliceosome | 62/1718 | 217/8465 | 1.99e-03 | 7.92e-03 | 4.90e-03 | 62 |
hsa0301813 | Prostate | BPH | RNA degradation | 29/1718 | 79/8465 | 5.17e-04 | 2.67e-03 | 1.65e-03 | 29 |
hsa0304015 | Prostate | BPH | Spliceosome | 62/1718 | 217/8465 | 1.99e-03 | 7.92e-03 | 4.90e-03 | 62 |
hsa0301822 | Prostate | Tumor | RNA degradation | 30/1791 | 79/8465 | 4.48e-04 | 2.35e-03 | 1.46e-03 | 30 |
hsa0304025 | Prostate | Tumor | Spliceosome | 66/1791 | 217/8465 | 7.53e-04 | 3.59e-03 | 2.23e-03 | 66 |
hsa0301832 | Prostate | Tumor | RNA degradation | 30/1791 | 79/8465 | 4.48e-04 | 2.35e-03 | 1.46e-03 | 30 |
hsa0304035 | Prostate | Tumor | Spliceosome | 66/1791 | 217/8465 | 7.53e-04 | 3.59e-03 | 2.23e-03 | 66 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LSM5 | SNV | Missense_Mutation | rs376563041 | c.29N>T | p.Ser10Leu | p.S10L | Q9Y4Y9 | protein_coding | tolerated(0.07) | benign(0.007) | TCGA-AO-A0J5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate | zoledronic | PD |
LSM5 | SNV | Missense_Mutation | c.90N>A | p.Met30Ile | p.M30I | Q9Y4Y9 | protein_coding | deleterious(0.02) | benign(0.428) | TCGA-BH-A0BZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR | |
LSM5 | SNV | Missense_Mutation | rs376563041 | c.29C>T | p.Ser10Leu | p.S10L | Q9Y4Y9 | protein_coding | tolerated(0.07) | benign(0.007) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
LSM5 | SNV | Missense_Mutation | novel | c.125G>A | p.Gly42Glu | p.G42E | Q9Y4Y9 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LSM5 | SNV | Missense_Mutation | novel | c.116C>T | p.Thr39Ile | p.T39I | Q9Y4Y9 | protein_coding | tolerated(0.05) | benign(0.211) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
LSM5 | SNV | Missense_Mutation | c.74N>T | p.Arg25Ile | p.R25I | Q9Y4Y9 | protein_coding | deleterious(0) | probably_damaging(0.912) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
LSM5 | SNV | Missense_Mutation | novel | c.85G>A | p.Val29Met | p.V29M | Q9Y4Y9 | protein_coding | tolerated(0.06) | possibly_damaging(0.734) | TCGA-56-7730-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | unknown | PD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |